Understanding the Role of Aspirin in Colorectal Cancer

For High-Definition, Click

Adjuvant treatment with aspirin seems to reduce the risk of recurrence in patients with colorectal cancer (CRC), according to emerging data. Furthermore, Axel Grothey, MD, notes, treatment with aspirin also affects the number of polyps that manifest in patients with familial adenomatous polyposis.

In general, Grothey notes, the evidence supporting aspirin is overwhelmingly positive, suggesting that COX-2 inhibitors can reduce recurrence in CRC. Moreover, research has tied aspirin’s efficacy to mutations in the PIK3CA gene. In ways, Grothey notes, aspirin works as a targeted agent for patients with PIK3CA mutations. As a result, more potent COX-2 inhibitors, such as celecoxib, are being examined in randomized trials in adjuvant CRC.

Heinz-Josef Lenz, MD, believes that PI3K testing should be performed more routinely, as it provides insight into the risk for recurrence. However, if a patient does not test positive for PIKC3A, Lenz does not feel that discontinuing treatment with aspirin is necessary. Overall, more data on markers of recurrence are needed but preliminary data regarding aspirin has been promising.

Related Videos
Shubham Pant, MD, MBBS
John L. Marshall, MD
Pamela L. Kunz, MD, associate professor, internal medicine (medical oncology), Yale School of Medicine; director, Center for Gastrointestinal (GI) Cancers, chief, GI Medical Oncology, Smilow Cancer Hospital, Yale Cancer Center
Suneel Kamath, MD
Suneel Kamath, MD
Rene Adam, MD, PhD
Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine
Olivia Aranha, MD, PhD
Michael Iglesia, MD, PhD
Petros Grivas, MD, PhD; and Chandler Park, MD, MSc, FACP